205 related articles for article (PubMed ID: 30614248)
1. The Impact of Socioeconomic Status on Voice Outcomes in Patients With Spasmodic Dysphonia Treated With Botulinum Toxin Injections.
Valenzuela D; Singer J; Lee T; Hu A
Ann Otol Rhinol Laryngol; 2019 Apr; 128(4):316-322. PubMed ID: 30614248
[TBL] [Abstract][Full Text] [Related]
2. Socioeconomic Variables of Patients with Spasmodic Dysphonia: A Preliminary Study.
O'Connell Ferster AP; Sataloff RT; Shewokis PA; Hu A
J Voice; 2018 Jul; 32(4):479-483. PubMed ID: 28927659
[TBL] [Abstract][Full Text] [Related]
3. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
[TBL] [Abstract][Full Text] [Related]
4. Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.
Meyer TK; Hu A; Hillel AD
Laryngoscope; 2013 Nov; 123 Suppl 6():S1-14. PubMed ID: 23818277
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated With Patient-perceived Hoarseness in Spasmodic Dysphonia Patients.
Hu A; Hillel A; Meyer T
J Voice; 2016 Nov; 30(6):769.e23-769.e26. PubMed ID: 26704415
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
Morzaria S; Damrose EJ
J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
Simpson CB; Lee CT; Hatcher JL; Michalek J
Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Failure of Botulinum Toxin Injection in Adductor Spasmodic Dysphonia.
Zhao K; Guillaud M; Hu A
Ann Otol Rhinol Laryngol; 2020 Oct; 129(10):996-1002. PubMed ID: 32468829
[TBL] [Abstract][Full Text] [Related]
9. Association of Laryngeal Botulinum Neurotoxin Injection With Work Productivity for Patients With Spasmodic Dysphonia.
Meyer TK; Spiekerman C; Kaye R; Blitzer A; Kamizi RS; Jiang L; Weaver EM
JAMA Otolaryngol Head Neck Surg; 2021 Sep; 147(9):804-810. PubMed ID: 34351425
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia.
Benninger MS; Gardner G; Grywalski C
Arch Otolaryngol Head Neck Surg; 2001 Sep; 127(9):1083-5. PubMed ID: 11556856
[TBL] [Abstract][Full Text] [Related]
11. Correlation of the Voice Handicap Index-10 (VHI-10) and Voice-Related Quality of Life (V-RQOL) in patients with dysphonia.
Romak JJ; Orbelo DM; Maragos NE; Ekbom DC
J Voice; 2014 Mar; 28(2):237-40. PubMed ID: 24321582
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
Tsuji DH; Takahashi MT; Imamura R; Hachiya A; Sennes LU
J Voice; 2012 Sep; 26(5):666.e7-12. PubMed ID: 21940146
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
14. Disease-specific self-efficacy in spasmodic dysphonia patients.
Hu A; Isetti D; Hillel AD; Waugh P; Comstock B; Meyer TK
Otolaryngol Head Neck Surg; 2013 Mar; 148(3):450-5. PubMed ID: 23300221
[TBL] [Abstract][Full Text] [Related]
15. New Perspective on Psychosocial Distress in Patients with Dysphonia: The Moderating Role of Perceived Control.
Misono S; Meredith L; Peterson CB; Frazier PA
J Voice; 2016 Mar; 30(2):172-6. PubMed ID: 25795347
[TBL] [Abstract][Full Text] [Related]
16. Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin.
Esposito M; Dubbioso R; Apisa P; Allocca R; Santoro L; Cesari U
Neurol Sci; 2015 Sep; 36(9):1679-82. PubMed ID: 25966878
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia.
Hogikyan ND; Wodchis WP; Spak C; Kileny PR
J Voice; 2001 Dec; 15(4):576-86. PubMed ID: 11792036
[TBL] [Abstract][Full Text] [Related]
18. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
Young DL; Halstead LA
J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
[TBL] [Abstract][Full Text] [Related]
19. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
[TBL] [Abstract][Full Text] [Related]
20. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
